Gut Check

Month: December 2020

Modulatory effects of the gut microbiome in cancer immunotherapy: A novel paradigm for blockade of immune checkpoint inhibitors

Notably, intestinal microbiota can cooperate with immune checkpoint inhibitors (ICIs) of its host, especially in enhanc-ing the efficacy of programmed death 1 (PD-1) protein and its ligand programmed death ligand 1 (PD-L1) blockade therapy for cancer. Herein, we review the dual function of gut microbiota in triggering GI cancers, its association with host immunity and its beneficial functions in modulation of cancer immunotherapy responses. Importantly, supplementation with specific probiotics or prebiotics and restoring the favorable intestinal microbi-ome by applying FMT or the prevention of the unfavorable bacteria by narrow-spectrum antibiotics may improve the effectiveness of ICIs in tumor control.

Postbiotics: A novel strategy in food allergy treatment

During the last two decades, the prevalence and severity of clinical appearances of food allergy (FA) have a significant rise. FA derives from a breakdown of immune tolerance. In recent year’s clinical evidence have shown that the probiotics have significant influences on FA by improving the immune tolerance. Besides, postbiotics due to their unique characteristics (safe profile, more shelf life, resistance to mammalian enzymes and stable to digestive system conditions), may have safety superiority against their parent live cells and as a novel strategy can be applied for improvement immune tolerance and treatment of FA without any undesirable side-effects or human opportunistic infections, particularly in infants and pediatrics.